<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132625</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922A1101</org_study_id>
    <nct_id>NCT01132625</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan</brief_title>
  <official_title>A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and
      pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>establish maximum tolerate dose (safety and tolerability)</measure>
    <time_frame>about 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by type, frequency and severity of adverse events</measure>
    <time_frame>about 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by RECIST</measure>
    <time_frame>about 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessed by Cmax, Tmax, AUC</measure>
    <time_frame>about 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessed by blood and tumor biomarkers at baseline and post AUY922</measure>
    <time_frame>about 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>AUY922</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <arm_group_label>AUY922</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced malignant solid tumors

          -  ECOG Performance Status of ≤ 2

          -  Patients must have the following laboratory values:

          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 8.5 g/dl, Platelets
             (plt) ≥ 100 x 109/L

          -  Potassium, Calcium, Magnesium, Phosphorus within normal limits or correctable with
             supplements

          -  AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN)

          -  Serum bilirubin ≤ 1.5 x ULN, Serum albumin &gt; 2.5g/dl, Serum creatinine≤ 1.5 x ULN or
             24-hour clearance ≥ 50 ml/min

          -  Able to sign informed consent and to comply with the protocol

        Exclusion Criteria:

          -  Patients with brain metastasis.

          -  Prior treatment with any HSP90 or HDAC inhibitor compound.

          -  Treatment with therapeutic doses of coumarin anticoagulants.

          -  Pregnant and lactating women.

          -  Severe and/or uncontrolled acute or chronic liver disease

          -  Severe and/or uncontrolled acute or chronic renal disease

          -  Chronically significant heart disease

          -  History (or family history) of long QT syndrome. QTc ≥ 450 msec on screening ECG,
             ischemic heart disease, heart fail, ECG abnormalities, atrial fibrillation, atrial
             flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de
             Pointes.

          -  Patients who are currently receiving treatment with any medication which has a
             relative risk or prolonging the QTcF interval or inducing Torsades de Pointes

          -  Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g
             Gilbert's syndrome).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSP90</keyword>
  <keyword>molecular chaperone</keyword>
  <keyword>advanced solid tumors</keyword>
  <keyword>Japan</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

